Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Genetic Testing Raises Complex Legal, Ethical, Social Issues

July 1, 1999
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 7
Volume 8
Issue 7

BALTIMORE-“However unfamiliar the territory, physicians, nurses, and other health care providers must understand the murky region surrounding genetic testing where legal, ethical, and social questions overlap science,” said Karen H. Rothenberg, JD, MPA, director of the Law and Health Care Program, University of Maryland School of Law. She spoke at a program on clinical cancer genetics held at Johns Hopkins University.

BALTIMORE—“However unfamiliar the territory, physicians, nurses, and other health care providers must understand the murky region surrounding genetic testing where legal, ethical, and social questions overlap science,” said Karen H. Rothenberg, JD, MPA, director of the Law and Health Care Program, University of Maryland School of Law. She spoke at a program on clinical cancer genetics held at Johns Hopkins University.

“Genetic testing produces data different from other kinds of medical information,” Ms. Rothenberg said. She referred to the distinctions as the “six P’s” (see Table ). Genetic information, she said, is “personal, powerful, potentially predictive, pedigree sensitive, permanent, and prejudicial.”

The Six P’s of Genetic Information

Genetic Information Is:

Personal (as unique as an individual’s DNA)

Powerful (or may appear to be)

Potentially predictive (of future health problems)

Pedigree sensitive (it is not just about individuals, but about their families, who may not want the information)

Permanent (currently, or at least not easily changed by gene therapy)

Prejudicial (historically used to discriminate against populations)

Legal issues that may crop up when dealing with genetic testing include informed consent, discrimination, privacy, liability, and family rights. She provided specific examples and advice on how to avoid potential legal problems.

 Informed consent has its benefits and risks, but its context is constantly changing, she said. For instance, the predictive value of a genetic test may not be known or may have varying usefulness in diagnosis. There is a risk of misinterpretation among patients or in the community, or there may be limited data on the effectiveness of preventive or interventional strategies.

 The effect on health behavior may not always be straightforward. Would a hypothetical test for lung cancer susceptibility, for example, empower or paralyze people? Would a negative test free people from the fear of lung cancer and so encourage them to smoke—leading to other smoking-related illnesses?

“There is great difficulty in quantifying social risk,” Ms. Rothenberg said. “Much depends on patients’ personal histories. The views of two people may differ depending on whether they see themselves as ‘healthy’ or a cancer patient.”

 Legal prohibitions on genetic discrimination in health insurance have been proposed and passed in some states, she said. Generally, these have stated that insurance companies may not require or request genetic tests, may not ask for results, may not base coverage or benefits on genetic testing, and may not consider genetic testing in determining rates.

While these laws were enacted to protect consumers, they share a number of problems. “Most focus on test results, but say nothing of family history or other sources of information,” she said (although a new Maryland law covers this point). “Half the people in the United States get their health insurance under ERISA, which is not included under state legal protection, so we need a federal solution. Now we’re trying to educate Congress so we can reap the benefit of the Human Genome Project.”

The federal Health Insurance Portability and Accountability Act (HIPAA, or the Kennedy-Kassebaum Act) states that genetic information cannot be considered a pre-existing condition, nor can it be used to determine insurance eligibility. But the bill says nothing about genetic privacy rights or about the practice of requesting genetic testing as a condition of medical coverage.

On the other hand, the Equal Employment Opportunity Commission has interpreted the Americans with Disability Act to say that a disability may be created on the basis of genetic information, citing predisposition to colon cancer as an example. However, this interpretation has not yet been tested in the courts.

“Thus we need a federal law saying that employers cannot discriminate on the basis of genetic information,” Ms. Rothenberg said. Congress might decide to deal with employment and health insurance issues together or by specific genetic legislation on each topic.

Family issues. “Perhaps the most complex questions arise not in Congress,” Ms. Rothenberg said, “but at the intersection of medical knowledge, ethical issues, and family dynamics.” The individual autonomy model that is a part of contemporary medical ethics “crumbles when testing genetics,” she said. “The family is the unit under discussion, not the individual.”

Both patients and their families may believe they have a right to know the outcome of genetic tests—and a right not to know, as well. Genetic information can throw a harsh light onto social and genetic relationships and intergenerational issues. Expectations of privacy may vary widely, and laws generally do not specifically immunize health care providers against lawsuits based on their giving or not giving genetic information.

“We value information in the health care system,” she said. “Doctors, genetic counselors, and nurses have to do good risk assessment with patients and then maintain good communication with their families when that is desired.”

Deciding on genetic testing for children depends on the disease and on the test. Children aren’t ordinarily tested for adult-onset diseases until they reach majority status. “Parental anxiety is not sufficient reason to test,” she said, although there may be a few cases in which medical benefits outweigh psychological harm.

“But there are professionals who believe it is medically appropriate to offer genetic testing if you are looking for a childhood disease, there is an effective intervention, and the test can be adequately interpreted,” she said.

Genetic information is already a part of family law and the court system. “When people fight each other in court, they want to win,” she said, and that means bringing any available evidence.

Besides the obvious area of paternity, Ms. Rothenberg said, genetic testing might be dragged into custody battles in divorce trials. “Could a mother with a mutation predisposing her to breast cancer, for example, be denied custody of her children because the father believes he will live longer?” she hypothesized. A court might rule it would be in “the best interest of the child” to live with the parent who did not have a genetic predisposition to disease.

Finally, Ms. Rothenberg asked, “how can law support health care providers in taking the right steps in the age of genetic information?” She gave this advice:

Disclose to patients the benefits, risks, and limitations of genetic testing. “Studies have show that if something goes wrong in the operating room, the patient is more likely to sue if prior communication was lacking,” she said.

Follow up and stay in contact with the patient after genetic testing. Establish and maintain a working doctor-patient relationship.

Maintain confidentiality.

Be aware of the risk to others of genetic information and talk to patients about those issues.

Anticipate potential legal, ethical, and social issues before testing.

Understand the dynamics of the patient’s family. Encourage family involvement but be aware of potential problems.

Avoid coercion by the patient’s family or by other health care providers to reveal test results.

Be aware of applicable state and federal laws.

Articles in this issue

Nasal Angiogenesis Inhibitor May Stop Kaposi’s Sarcoma
Surgeon’s Perspective on Neoadjuvant Chemo for Breast Cancer
STAR Breast Cancer Prevention Trial Begins Enrollment
Studies Suggest New Approaches in Hereditary Ovarian Cancer
Lycopene Beneficial in Prostate Cancer
Komen Launches REMEMBER

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Related Content

The test may help identify patients with microsatellite instability-high colorectal cancer who benefit from nivolumab therapy alone or with ipilimumab.

Idylla CDx MSI Test Earns FDA Approval in MSI-H Colorectal Cancer

Roman Fabbricatore
September 16th 2025
Article

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 16th 2025
Podcast

Patients with BRAF fusion papillary thyroid cancer also had clinical benefit with the therapy.

How Does Plixorafenib Compare With Other BRAF-Mutant Thyroid Cancer Agents?

Tim Cortese
September 16th 2025
Article

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 16th 2025
Podcast

Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

I-DXd Shows “Impressive” Responses in Extensive-Stage SCLC

Russ Conroy
September 16th 2025
Article

While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.

The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

Tim Cortese
September 16th 2025
Article
Related Content

The test may help identify patients with microsatellite instability-high colorectal cancer who benefit from nivolumab therapy alone or with ipilimumab.

Idylla CDx MSI Test Earns FDA Approval in MSI-H Colorectal Cancer

Roman Fabbricatore
September 16th 2025
Article

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 16th 2025
Podcast

Patients with BRAF fusion papillary thyroid cancer also had clinical benefit with the therapy.

How Does Plixorafenib Compare With Other BRAF-Mutant Thyroid Cancer Agents?

Tim Cortese
September 16th 2025
Article

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 16th 2025
Podcast

Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

I-DXd Shows “Impressive” Responses in Extensive-Stage SCLC

Russ Conroy
September 16th 2025
Article

While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.

The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

Tim Cortese
September 16th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.